Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Seffalair Spiromax

Seffalair Spiromax 12.75 micrograms/100 micrograms inhalation powder Seffalair Spiromax 12.75 micrograms/202 micrograms inhalation powder · Abschnitt 4.8 · PDF-Seite 9

HOS-142741 · Präparat HOS-098862

System Organ Class Adverse reaction Frequency Oral candidiasisa Common1 Influenza Common Nasopharyngitis Common Rhinitis Common Infections and infestations Sinusitis Common Pharyngitis Uncommon Respiratory tract infection Uncommon Oesophageal candidiasis Rare Cushing's syndrome, Cushingoid features, Endocrine disorders adrenal suppression and growth retardation Rare1 in children and adolescents Metabolism and nutrition Hypokalaemia Common2 disorders Hyperglycaemia Uncommon Anxiety Uncommon Insomnia Uncommon Psychiatric disorders Behavioural changes, including hyperactivity Uncommon and irritability, especially in children Headache Common Nervous system disorders Dizziness Common Tremor Uncommon Cataract Uncommon Eye disorders Glaucoma Rare1 Vision blurred Not known1 Palpitations Uncommon1 Tachycardia Uncommon Atrial fibrillation Uncommon Cardiac disorders Cardiac arrhythmias (including supraventricular tachycardia and Rare extrasystoles) Cough Common Throat irritation Common Hoarseness/dysphonia Common Respiratory, thoracic and Oropharyngeal pain Common mediastinal disorders Rhinitis allergic Uncommon Nasal congestion Uncommon Paradoxical bronchospasm Rare1 Abdominal pain upper Uncommon Gastrointestinal disorders Dyspepsia Uncommon Skin and subcutaneous Dermatitis contact Uncommon tissue disorders Musculoskeletal and Back pain Common connective tissue disorders Myalgia Common

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.